Fig. 4
From: Preventing autosomal-dominant hearing loss in Bth mice with CRISPR/CasRx-based RNA editing
Improvement in auditory function via CasRx in Bth mice. a ABR waveforms recorded at 8 kHz at 4 weeks in the Tmc1Bth/+ injected right ear, the non-injected left ear, and the wild-type ear. The green traces indicate the threshold. b, c Tone-burst and click-evoked ABR thresholds at 4, 8 weeks in Tmc1+/+ (Green), Tmc1Bth/+ + AAV-CasRx + sgRNA3 (Blue), and Tmc1Bth/+ non-injected contralateral (Red) ears. Mean ABR thresholds were significantly reduced in ears injected with AAV-CasRx + sgRNA3 (~5 × 109 vg of AAV) compared to non-injected Tmc1Bth/+ ears after 4 and 8 weeks. Statistical analysis was performed by two-way ANOVA with Tukey’s post hoc test for multiple comparisons. d DPOAE thresholds at 4, 8 weeks in Tmc1Bth/+ + AAV-CasRx + sgRNA3 (Blue) and Tmc1Bth/+ untreated contralateral (Red) ears. DPOAE thresholds were significantly reduced in the ears injected with AAV-CasRx + sgRNA3 (~5 × 109 vg of AAV) at two frequencies. Statistical analysis was performed by two-way Bonferroni’s multiple comparisons test. *p < 0.05, **p < 0.01, ***p < 0.001, and ****p < 0.0001. Values and error bars represent the mean ± SD
